Gabelli Funds LLC Buys 54 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Gabelli Funds LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.0% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,859 shares of the biopharmaceutical company’s stock after purchasing an additional 54 shares during the quarter. Gabelli Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $1,789,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Eudaimonia Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 11 shares in the last quarter. Team Hewins LLC raised its position in shares of Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 11 shares during the last quarter. Angeles Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 11 shares during the last quarter. Drive Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares during the last quarter. Finally, MCF Advisors LLC raised its position in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,397,202. The disclosure for this sale can be found here. Insiders have sold 65,074 shares of company stock valued at $64,546,123 in the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on REGN. Argus boosted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $1,040.00 to $1,180.00 and gave the stock a “buy” rating in a research report on Thursday, July 18th. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Finally, Piper Sandler boosted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,074.95.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $14.44 during midday trading on Friday, hitting $1,078.63. The company’s stock had a trading volume of 380,897 shares, compared to its average volume of 386,591. Regeneron Pharmaceuticals, Inc. has a 12 month low of $723.56 and a 12 month high of $1,106.16. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $118.85 billion, a price-to-earnings ratio of 31.87, a price-to-earnings-growth ratio of 2.22 and a beta of 0.13. The company has a 50 day moving average of $1,033.85 and a two-hundred day moving average of $977.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.36 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.